CAPALBO, EUGENIO
 Distribuzione geografica
Continente #
EU - Europa 105
NA - Nord America 63
AS - Asia 22
AF - Africa 2
SA - Sud America 1
Totale 193
Nazione #
US - Stati Uniti d'America 61
IE - Irlanda 37
IT - Italia 37
RU - Federazione Russa 16
SG - Singapore 15
FI - Finlandia 4
FR - Francia 3
SE - Svezia 3
BE - Belgio 2
CA - Canada 2
CI - Costa d'Avorio 2
CN - Cina 2
IN - India 2
CL - Cile 1
DE - Germania 1
GB - Regno Unito 1
HK - Hong Kong 1
LT - Lituania 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 193
Città #
Dublin 37
Santa Clara 28
Singapore 13
Siena 10
Chandler 7
Ashburn 3
Helsinki 3
Rome 3
Sciacca 3
Abidjan 2
Affile 2
Brussels 2
Florence 2
Fremont 2
Montemurlo 2
Naples 2
New Delhi 2
Ottawa 2
Palermo 2
Princeton 2
Shanghai 2
Verdellino 2
Arona 1
Boardman 1
Hong Kong 1
Lappeenranta 1
Los Angeles 1
Milan 1
Monteriggioni 1
Moscow 1
Palestrina 1
Paris 1
Ravenna 1
San Mateo 1
Sansepolcro 1
Santiago Metropolitan 1
Tashkent 1
Woodbridge 1
Totale 149
Nome #
Anti-IL23for nail psoriasis in real life: Results of efficacy and safety during a 52-week period 65
Pso-Reg: a web registry for psoriasis in real life 55
Apremilast in Patients Difficult to Treat: A Multicentric Real-Life Long-Term Experience 29
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study 25
Risk of Skin Cancer in Patients with Psoriasis: Single-Center Retrospective Study Comparing Anti-TNFα and Phototherapy 17
Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg? 17
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation 10
Totale 218
Categoria #
all - tutte 1.400
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.400


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 0 0 0 3 2 4
2022/202335 2 3 5 2 5 3 1 4 2 0 6 2
2023/202483 4 1 2 18 6 10 25 3 1 0 3 10
2024/202591 0 5 22 17 35 12 0 0 0 0 0 0
Totale 218